Close Menu

Keith Robison has a post on his Omics! Omics! blog about Roche's seemingly unquenchable thirst for acquisition targets. Robison recaps the recent acquisitions of 454 and NimbleGen, as well as the company's currently-in-play bid for Ventana, and ponders how these units could function together as well as what kind of technology might be next on Roche's shopping list.

 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.

US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.

The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.

In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.